N. Zaki

Fulranumab as Adjunctive Therapy for Cancer-Related Pain: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.

N. Slatkin, J. Thipphawong, P. Sanga, 2019, The journal of pain : official journal of the American Pain Society.

Self-reported review of the value of esketamine in patients with treatment-resistant depression: Understanding the patient experience in the STRIVE Study

C. Demuro, E. Daly, J. Abell, 2020, Psychiatry Research.

Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study

W. Drevets, S. Wilkinson, G. Sanacora, 2023, Neuropsychopharmacology.

Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies

J. Haeussler, J. Thipphawong, P. Sanga, 2019, Current medical research and opinion.

Safety and Efficacy of Fulranumab in Osteoarthritis of the Hip and Knee: Results From Four Randomized, Double-blind, Placebo-controlled Phase III Studies

J. Haeussler, J. Thipphawong, P. Sanga, 2019 .

(382) Efficacy, safety, and tolerability of Fulranumab as adjunctive therapy for cancer-related pain: a randomized, double-blind, placebo-controlled, multicenter study.

N. Slatkin, J. Thipphawong, P. Sanga, 2016, The journal of pain : official journal of the American Pain Society.